Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.

World journal of gastroenterology - 7 Oct 2005

Economou Michalis, Manolakopoulos Spilios, Trikalinos Thomas-A, Filis Spyros, Bethanis Sotiris, Tzourmakliotis Dimitrios, Avgerinos Alec, Raptis Sotiris, Tsianos Epameinondas-V

Abstract excerpt

AIM: The HBeAg negative form of chronic hepatitis B (CHB) predominates in the Mediterranean area and has a rising frequency in Europe and North America. At present there are three approved therapies for patients with CHB: interferon-alpha (IFN-alpha), lamivudine and adefovir dipivoxil. Unfortunat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Interferon-alpha

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 16270403
DOI: 10.3748/wjg.v11.i37.5882
PMCID: PMC4479694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16270403-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.PMID 16270403Read ↗

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.Semantic proximity Read ↗

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy.Semantic proximity Read ↗

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.Semantic proximity Read ↗

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Semantic proximity Read ↗

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.Semantic proximity Read ↗

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Semantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.